50 results about "Viral pneumonia" patented technology

The invention discloses a biologically safe and degradable cerium-based tannic acid nano-enzyme as well as a preparation method and application thereof. The nano-enzyme can be administrated through a non-invasive nasal cavity. In an area with excessive ROS, thioketone on CeTA-k1tkP is destroyed, PEG is removed, hydrogen bonds of an amino acid sequence are allowed to form beta-sheet, the beta-sheet is accumulated at an inflammation part, and a fiber or network structure is formed. Meanwhile, CeTA-k1tkP shows enzyme-like capacity, ROS is effectively eliminated, inflammation is effectively relieved, and systemic immunosuppression is avoided at the same time. In an influenza A (Flu A) virus or Sendai virus (SeV) mediated viral pneumonia model, CeTA-k1tkP can generate responsive deformation in inflammatory lung tissues, so that the nano-enzyme effectively decomposes ROS (reactive oxygen species). In addition, the CeTA-k1tkP can relieve bacterial inflammation and reduce tissue damage in a mouse viral pneumonia model with secondary bacterial infection.

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

The invention relates to the technical field of biomedicine, in particular to a molecular marker for diagnosis and treatment of severe viral pneumonia. The TMEM176B and various interacting genes show good prognosis prediction value, and a reliable molecular marker is provided for early judgment and screening of severe viral pneumonia; the TMEM176B can be used as a severe viral pneumonia intervention target, and has important value for clinical transformation and research and development of future drug targets.

The invention discloses an AI-based viral pneumonia auxiliary diagnosis method and system, and relates to the field of pneumonia diagnos.The method comprises the steps that abnormal state monitoring is conducted on target people in a target area, and when it is detected that a target human body is in the abnormal state within a preset time period and the occurrence frequency of abnormal behaviors exceeds a preset threshold value, the target human body is judged to be in the abnormal state; mapping the occurrence position, the moving track and the real-time people flow density into a three-dimensional building model to obtain space environment associated data; inputting the space environment associated data into a propagation prediction model to obtain a propagation risk probability of each target sub-region in the target region; and marking the target sub-region of which the propagation risk probability is greater than a preset risk threshold as a target risk region, and generating first early warning information containing the target risk region and the target human body. By implementing the method, the accuracy of the viral pneumonia early warning information can be improved.

An anti-Cyclophilin A monoclonal antibody, and a use thereof in treating viral pneumonia. Provided is a hybridoma cell SQHC14 secreting an anti-CypA monoclonal antibody, having the preservation number CGMCC No. 45049; also provided is an anti-CypA monoclonal antibody SQHC14 secreted by the hybridoma cell SQHC14; the monoclonal antibody SQHC14 can specifically recognize CypA, and inhibit secretion of inflammatory factors and leukocyte migration induced by viral infection.

The invention belongs to the technical field of medicine preparation, and particularly relates to a nitraria tangutorum composite medicine, which is prepared from the following raw materials in parts by weight: 10 to 30 parts of nitraria tangutorum, 0 to 30 parts of herba elsholtziae, 0 to 20 parts of pink reineckea herb and 0 to 20 parts of stevia rebaudiana. The preparation method comprises the following steps: respectively cleaning and drying the sophora davidii, the elsholtzia, the pink reineckea herb and the stevia rebaudiana according to the proportion, crushing into powder, and uniformly mixing to obtain raw material powder of the sophora davidii combined medicine. The raw material powder can be further prepared into dosage forms such as granules, tablets, capsules or oral liquid. The nitraria tangutorum var. Davidii combined medicine is applied to treatment of pneumonia including bacterial pneumonia, viral pneumonia and the like.

The application discloses application of an aloe oral liquid in preparation of a medicine for treating acute viral pneumonia. A preparation method of the aloe oral liquid comprises the following steps: after fresh aloe leaves are washed and peeled, the fresh aloe leaves are scraped to prepare fresh aloe gel; the fresh aloe gel liquid is placed in a light reaction tank, and is subjected to blue light, red light and no light alternately under low-temperature conditions; the fresh aloe gel after light treatment is pumped into a decocting and concentrating tank, and is concentrated to a supernatant with a density of 1.10 kg / m 3 1.2 kg / m 3 between, is filled and sealed after cooling, and is sterilized to obtain the aloe oral liquid. The application promotes clinical indications of fresh aloe leaves, provides a new drug selection for clinical treatment of acute viral pneumonia, provides a technical reference for industrial production of fresh aloe leaf medicine products, and promotes inheritance and innovation of traditional Chinese medicines with clinical application as a foothold.

The present invention discloses the use of MxA or its binding antibody or fragment in the preparation of a diagnostic reagent for warning an individual of severe viral pneumonia. The diagnostic kit for diagnosing an individual as belonging to severe viral pneumonia contains a diagnostic reagent, the diagnostic reagent contains MxA or its binding antibody or fragment, and the MxA or its binding antibody or fragment is compared with the individual's blood, plasma or serum sample for detection. In the invention, the sensitivity and specificity of MxA binding antibody or its fragment in identifying severe viral pneumonia from the pneumonia population are 85% and 89.1%, and MxA is used as a biomarker for the diagnosis of severe viral pneumonia, and its diagnostic detection effect is very outstanding.

To provide a method and a drug for treating viral pneumonia.SOLUTION: A pharmaceutical composition comprises a therapeutically effective amount of one or more compounds selected from the group consisting of a component of plasminogen activation pathway, a compound capable of activating plasminogen, a compound mimicking the activity of plasminogen or plasmin, a compound capable of upregulating the expression of plasminogen or an activator of plasminogen, an analog of plasminogen, an analog of plasmin, an analog of tPA or uPA, and an antagonist of fibrinolysis inhibitor.SELECTED DRAWING: None

The invention discloses a traditional Chinese medicine preparation for treating viral pneumonia. The traditional Chinese medicine preparation comprises the following components in parts by weight: 10-20 parts of ginseng, 9-15 parts of parasitic loranthus, 4-6 parts of schisandra chinensis, 6-9 parts of gastrodia elata, 6-9 parts of cassia twig, 6-9 parts of divaricate saposhnikovia root, 3-4.5 parts of prepared fructus evodiae, 10-20 parts of salvia miltiorrhiza, 6-9 parts of angelica sinensis, 6-9 parts of ligusticum wallichii, 8-12 parts of cortex moutan, 6-9 parts of radix paeoniae rubra, 6-9 parts of pericarpium citri reticulatae, 6-9 parts of rhizoma pinellinae praeparata and 6-9 parts of honey-fried The traditional Chinese medicine preparation disclosed by the invention is high in effective rate, can quickly relieve inflammatory response and remarkably reduce release of inflammatory mediators, and can quickly bring down a fever of a patient, and the average time is about 29 hours.

The present invention relates to the use of daphnetin in the preparation of a drug for treating viral pneumonia. When daphnetin or a pharmaceutically acceptable salt or solvate thereof is used for the treatment of viral pneumonia, it has a good therapeutic effect. The present invention also provides the use of daphnetin or a pharmaceutically acceptable salt or solvate thereof and a glucocorticoid in the preparation of a drug for treating viral pneumonia, as well as a pharmaceutical composition containing the two and a preparation method thereof. When daphnetin and a glucocorticoid are used in combination for the treatment of viral pneumonia, the two have a synergistic effect and can significantly improve the efficacy of viral pneumonia.

This invention provides a traditional Chinese medicine composition for treating viral pneumonia in calves, its preparation method, and its application, belonging to the field of veterinary drug technology. The traditional Chinese medicine composition provided by this invention comprises the following raw materials in parts by weight: 15-20 parts of Gentiana scabra, 15-20 parts of Gardenia jasminoides, 15-20 parts of Scutellaria baicalensis, 10-15 parts of Bupleurum chinense, 25-35 parts of Rehmannia glutinosa, 25-35 parts of Plantago asiatica, 15-20 parts of Alisma plantago-aquatica, 25-35 parts of Akebia trifoliata, 10-15 parts of Angelica sinensis, 25-35 parts of Smilax glabra, 15-20 parts of Dioscorea hypoglauca, 25-35 parts of Dictamnus dasycarpus, and 10-15 parts of Glycyrrhiza uralensis (processed). The traditional Chinese medicine composition of this invention can effectively treat viral pneumonia in calves, and also has advantages that antibiotics cannot possess, such as being green and safe, residue-free, having few toxic side effects, low cost, convenient production, and being less likely to produce drug-resistant bacteria.

The invention discloses application of a polygonatum odoratum polysaccharide extract in preparation of a medicine for treating viral pneumonia, and belongs to the technical field of medicines. Through experiments, the applicant discovers that the polygonatum odoratum polysaccharide extract can significantly reduce the fluorescence intensity of neutrophils and macrophages in poly (I: C) induced zebrafish viral pneumonia model swimming sacs, has an obvious antiviral effect on zebrafish, can reduce the expression of pro-inflammatory factors tnf alpha, il6 and il12, has an obvious anti-inflammatory effect, and can be used for preparing anti-inflammatory drugs for treating zebrafish viral pneumonia. The compound is expected to be used for preparing anti-viral pneumonia drugs.

The application relates to an application of a traditional Chinese medicine composition in a drug for viral pneumonia, which comprises 10-15 parts of wind-preventing, 10-15 parts of perilla leaf, 2-6 parts of Ephedra, 7-9 parts of Schisandra chinensis, 7-9 parts of white ginkgo, 7-9 parts of bitter almond, 7-9 parts of purple aster, 7-9 parts of dogwood fruit and 7-9 parts of lily of the valley. The traditional Chinese medicine composition can obviously inhibit the increase of the lung index of respiratory syncytial virus (RSV) infected mice and has a better treatment effect on viral pneumonia.

The present invention relates to the field of pharmaceutical applications, and in particular to a marker for viral pneumonia and its application, wherein the marker for viral pneumonia is prostaglandin E2 and / or prostaglandin M. The present invention uses prostaglandin E2 and / or prostaglandin M as markers for viral pneumonia, and the use of cyclooxygenase II inhibitors can effectively and quickly reduce prostaglandins, reverse the progression of common and severe cases, block the occurrence of critical illness, promote viral conversion to negative, pneumonia absorption and health recovery. The drug will expand its clinical use scope upon further confirmation of its efficacy, incorporate the treatment method into clinical diagnosis and treatment plans, and provide new strategies and diagnosis and treatment methods for the comprehensive treatment of new coronary pneumonia.

The application discloses a drug delivery system targeting lung alveolus microenvironment oxidation and reduction as well as a preparation method and application thereof, and comprises nanoparticles self-assembled by amphiphilic GSH-(oxi)PEI-PCL polymers, wherein the nanoparticles load fat-soluble drugs or fluorescent dyes, GSH in the amphiphilic GSH-(oxi)PEI-PCL polymers is connected with (oxi)PEI-PCL through a disulfide bond, and the (oxi)PEI-PCL is PEI-PCL subjected to partial oxidation. The pharmacodynamic test result shows that the drug delivery system can realize passive targeting aggregation of drugs in a lesion and microenvironment oxidation and reduction sensitive distribution, meanwhile, the drug delivery system shows an antioxidation effect in a lesion microenvironment and intracellular, realizes more accurate drug distribution effect and in-vivo treatment effect, and provides a new drug route for treatment of lung diseases such as premature lung dysplasia, bacterial / viral pneumonia or burn inhalation lung injury.

The use of cellular microparticles in the treatment of respiratory viral pneumonia has been disclosed. Tumor cell-derived microparticles (MPs) include cellular vesicles released by apoptotic tumor cells. The cellular vesicles express spike protein-binding receptors on their surfaces. MPs have high biosafety. In addition, it has been found that the receptors on the surface of microparticles have virus adsorption ability, and macrophages can efficiently take up MPs, which can be used to treat viral pneumonia.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating lung-spleen qi deficiency in the recovery stage of viral pneumonia and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-30 parts of astragalus membranaceus, 3-20 parts of honeysuckle, 3-18 parts of scutellaria baicalensis, 3-18 parts of radix bupleuri, 6-30 parts of radix pseudostellariae, 6-30 parts of white poria, 6-30 parts of honey and bran fried bighead atractylodes rhizome, 6-30 parts of eupatorium, 3-18 parts of divaricate saposhnikovia root and 3-18 parts of honey-fried licorice root. The traditional Chinese medicine composition disclosed by the invention is precise and appropriate in compatibility, has the effects of tonifying qi, clearing and dredging, strengthening the spleen, consolidating superficies and the like, effectively relieves the symptom of qi deficiency of the lung and the spleen of a viral pneumonia convalescent patient and a plurality of related physiological indexes, and is widely praised by the patient and has an exact curative effect. Under the guidance of traditional Chinese medicine theories and clinical experience, all the raw material medicines and proportions are selected, the pure traditional Chinese medicine preparation is adopted, toxic and side effects are avoided, the aim of treating viral pneumonia in the recovery period is achieved, and the patient acceptability is high.

The invention belongs to the technical field of preparation of peptides, and particularly relates to a spirulina peptide, a preparation method, a product and application. The invention provides a spirulina peptide. The spirulina peptide comprises a first algae peptide, a second algae peptide, a third algae peptide, a fourth algae peptide and a fifth algae peptide. According to the preparation method of the spirulina peptide provided by the technical scheme, the neutral protease can preliminarily decompose protein in spirulina, the binding structure of the protein and polysaccharide is destroyed, and macromolecular protein is decomposed into medium-sized peptide fragments. Alkaline protease can deeply hydrolyze protein to generate the antiviral pneumonia active peptide with biological activity. And the papain can accurately regulate and control the molecular weight of the peptide fragment, so that the generated peptide fragment has relatively high water solubility and emulsifying activity, and the antiviral effect is high. Results of embodiments show that the spirulina peptide provided by the invention has the efficacy of resisting viral pneumonia.

The invention discloses an application of an aloe oral liquid in preparation of a medicine for treating acute viral pneumonia. The preparation method of the aloe oral liquid comprises the following steps: cleaning and peeling fresh aloe leaves, and scraping to prepare fresh aloe gel; putting the fresh aloe gel liquid into an illumination reaction tank, and carrying out blue light, red light and dark alternate treatment under a low-temperature condition; pumping the fresh aloe gel subjected to illumination treatment into a decoction concentration tank, concentrating until the liquid medicine is clear liquid with the density of 1.10 kg / m < 3 > to 1.2 kg / m < 3 >, cooling, filling, sealing and sterilizing to obtain the aloe gel. Clinical indications of the fresh aloe leaves are promoted, a new medication choice is provided for clinical treatment of acute viral pneumonia, technical reference is provided for industrial production of fresh aloe leaf medicine products, and traditional Chinese medicine inheritance and innovation with clinical application as a foothold are promoted.

The present invention relates to a long-chain fatty acyl monoterpenoid compound, a preparation method thereof, and uses thereof in the preparation of anti-complement drugs and anti-viral pneumonia drugs. The long-chain fatty acyl monoterpenoid compound has a chemical structure with the following general structural formula: The R group is hexadecyl or tetradecyl. Through in vitro anti-complement activity tests, the results show that the above-mentioned long-chain fatty acyl monoterpenoid compound has a strong inhibitory effect on the classical pathway of the complement system (see Table 1). (3S,5R,6S,7E)-3-tetradecanoate-5,6-epoxy-β-ionone has been confirmed through in vivo animal experiments to have a good therapeutic effect on viral pneumonia in mice induced by influenza A virus H1N1.

The present invention refers to an in vitro method for identifying biomarkers or biomarker signatures for the differential diagnosis between viral and bacterial pneumonia in a patient, for the differential diagnosis between viral and bacterial pneumonia in a patient and / or for selecting a therapy for a patient suffering from pneumonia.

The present invention relates to the technical field of risk assessment and prediction of viral pneumonia, and in particular to a risk assessment and prediction system based on viral pneumonia. The system is used to perform the following steps: collect original data of viral pneumonia from target patients with viral pneumonia to obtain original target patient data, wherein the original target patient data includes CT image data and original clinical data; perform lung region segmentation on the CT image data to obtain a lung mask image; obtain an unlabeled lung CT image; use the unlabeled lung CT image to predict the lesion region to obtain an initial lesion region prediction map. The present invention avoids the interference of irrelevant information by focusing the system's attention on key lesion areas, and captures the dynamic development process of the patient's condition over time, thereby more accurately predicting the patient's future condition development trend, thereby improving the system's sensitivity and the accuracy of risk assessment and the system's predictive ability.

The invention discloses a drug delivery system targeting alveolar microenvironment redox and a preparation method and application thereof.The drug delivery system comprises nanoparticles formed by self-assembly of an amphiphilic GSH-(oxi) PEI-PCL polymer, fat-soluble drugs or fluorescent dyes are loaded in the nanoparticles, GSH and (oxi) PEI-PCL in the amphiphilic GSH-(oxi) PEI-PCL polymer are connected through a disulfide bond, and the lipid-soluble drugs or fluorescent dyes are loaded in the nanoparticles. And the (oxi) PEI-PCL is the PEI-PCL subjected to partial oxidation. Pharmacodynamic test results show that the drug delivery system provided by the invention can realize passive targeting aggregation in a focus and microenvironment redox sensitive distribution of the drug, simultaneously shows antioxidant effects in the focus microenvironment and cells, realizes a relatively exact drug distribution effect and an in-vivo treatment effect, and has a wide application prospect. The invention provides a new drug approach for the treatment of lung diseases such as premature lung dysplasia, bacterial / viral pneumonia or burn inhalation lung injury and the like.

In order to solve the problems that an existing viral pneumonia related prediction model lacks accurate distinguishing of disease grading, model construction depends on laboratories and iconography data, and interpretability is insufficient, the invention provides an instant interpretable viral pneumonia disease grading distinguishing model construction method based on symptoms and signs. Comprising the following steps: acquiring clinical information of a subject, and constructing a sample data set; determining N preliminary clinical manifestation variables, and screening out M variables as clinical symptom sign feature vectors; respectively constructing a plurality of machine learning models, and determining an optimal model; the M clinical symptom sign feature vectors are incorporated into an optimal model, and a viral pneumonia condition grading discrimination model is established; carrying out SHAP interpretability analysis on the optimal model; and constructing an ordered logistic regression model, drawing a normogram, and displaying scores corresponding to different clinical symptom sign feature vectors and illness state grading discrimination probabilities according to the normogram, so as to realize accurate identification of early illness states and clinical convenience operability.

The invention provides a traditional Chinese medicine tea composition for improving viral pneumonia and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine, the traditional Chinese medicine tea composition comprises the following components: 11-18 parts of perilla leaf, 7-13 parts of honeysuckle, 7-13 parts of polygonatum odoratum, 5-12 parts of scorched hawthorn fruit, 4-8 parts of platycodon grandiflorum, 3-7 parts of pericarpium citri reticulatae, 3-7 parts of liquorice, 3-7 parts of chrysanthemum, 2-5 parts of osmanthus fragrans, 0.3-0.6 part of stevia rebaudiana, and 6-14 parts of black tea. An anti-inflammatory effect experiment of THP-1 cells proves that the traditional Chinese medicine tea composition has an improvement effect on viral pneumonia, specifically, the traditional Chinese medicine tea composition can effectively reduce IL-6 expression and has good anti-inflammatory activity; the expression of inflammatory indexes NO and IL-6 of RAW264.7 cells induced by lipopolysaccharide LPS is obviously reduced; the traditional Chinese medicine tea composition can be applied to preparation of anti-virus pneumonia products.

The invention relates to a traditional Chinese medicine composition for treating common cold or influenza and a preparation method thereof, the traditional Chinese medicine composition is prepared from 5-30 parts by weight of honeysuckle, 5-30 parts by weight of fructus forsythiae, 1-20 parts by weight of radix bupleuri, 1-20 parts by weight of radix puerariae, 1-15 parts by weight of mint, 1-10 parts by weight of honey-fried ephedra and 1-5 parts by weight of licorice. The traditional Chinese medicine composition has a good effect of treating viral pneumonia caused by influenza viruses, and the preparation method of the traditional Chinese medicine composition is simple and suitable for large-scale production and popularization.

This invention relates to the field of compound essential oils of traditional Chinese medicine, and particularly to a compound essential oil of traditional Chinese medicine for the adjuvant intervention against Streptococcus pneumoniae and its preparation method. The raw materials include the following by weight: 3-8 parts of patchouli essential oil; 2-6 parts of clove essential oil; 2-5 parts of costus root essential oil; 2-6 parts of nard essential oil; 3-7 parts of calamus essential oil; 1-4 parts of asarum essential oil; 3-8 parts of peppermint essential oil; 2-6 parts of artemisia essential oil; 3-7 parts of eupatorium essential oil; 45-80 parts of base oil; 2-5 parts of solubilizer; and 1-3 parts of penetration enhancer. This invention addresses the core issues of "respiratory inflammation, sputum accumulation, and decreased body defense" caused by Streptococcus pneumoniae. Through the scientific formulation of active molecules from nine kinds of Chinese herbal essential oils, a comprehensive synergistic system is formed, which has the functions of "antibacterial and antiviral, anti-inflammatory and lung-clearing, expectorant and cough-relieving, and enhanced defense." It features strong synergistic activity of active molecules, high specificity, high retention and utilization rate of active molecules, safe and convenient use, wide applicability, and simple preparation process.

The traditional Chinese medicine composition is prepared from 7.5 g of gypsum, 3 g of herba ephedrae, 4.5 g of fried semen armeniacae amarae, 1.5 g of radix glycyrrhizae, 5 g of cortex magnoliae officinalis, 7.5 g of rhizoma atractylodis fried with bran, 5 g of fried semen tsaoko, 4.5 g of rhizoma pinellinae praeparata, 7.5 g of poria cocos, 5 g of radix astragali, 5 g of semen lepidii, 5 g of radix paeoniae rubra, 5 g of agastache rugosus and 2.5 g of radix et rhizoma rhei.